Loading…
Scribe Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in SCTX.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CARLCarlsmed Inc | $16.88 | — | 5.5x | — | -66.14% | $460.87M |
| MASS908 Devices Inc. | $11.18 | — | 3.1x | — | -24.95% | $462.11M |
| AVIRAtea Pharmaceuticals, Inc. | $5.64 | — | 2.2x | — | -58.14% | $452.35M |
| SGHTSight Sciences, Inc. | $8.50 |
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Company description provided by Yahoo Finance.
| — |
| 8.8x |
| — |
| -48.42% |
| $468.25M |
| SRTAStrata Critical Medical, Inc. | $5.34 | — | 1.7x | — | -9.22% | $472.41M |
| QTTBQ32 Bio Inc. | $15.03 | 4.8x | 3.4x | — | 72.14% | $447.44M |